Stock Analysis

How Do Analysts See Chimerix, Inc. (NASDAQ:CMRX) Performing In The Next Couple Of Years?

In December 2018, Chimerix, Inc. (NASDAQ:CMRX) announced its latest earnings update, which showed company earnings became less negative compared to the previous year's level - great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts perceive Chimerix's earnings growth outlook over the next few years and whether the future looks brighter. I will be using net income excluding extraordinary items in order to exclude one-off volatility which I am not interested in.

See our latest analysis for Chimerix

Market analysts' consensus outlook for next year seems relatively muted, with earnings continuing to flop around in the negative territory, arriving at -US$75.2m in 2020. Additionally, earnings are expected to fall further in the following year, before bouncing back up again to -US$71.7m in 2022.

NasdaqGM:CMRX Past and Future Earnings, April 25th 2019
NasdaqGM:CMRX Past and Future Earnings, April 25th 2019

Although it’s useful to be aware of the growth rate each year relative to today’s value, it may be more beneficial estimating the rate at which the business is growing every year, on average. The pro of this method is that we can get a better picture of the direction of Chimerix's earnings trajectory over the long run, irrespective of near term fluctuations, be more volatile. To calculate this rate, I put a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is 13%. This means that, we can anticipate Chimerix will grow its earnings by 13% every year for the next couple of years.

Advertisement

Next Steps:

For Chimerix, there are three key factors you should further research:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does CMRX's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of CMRX? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqGM:CMRX

Chimerix

A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States.

Flawless balance sheet low.

Advertisement

Weekly Picks

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.7% undervalued
10 users have followed this narrative
5 users have commented on this narrative
1 users have liked this narrative
RO
Robbo
FID logo
Robbo on Fiducian Group ·

Fiducian: Compliance Clouds or Value Opportunity?

Fair Value:AU$126.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WO
WVVI logo
woodworthfund on Willamette Valley Vineyards ·

Willamette Valley Vineyards (WVVI): Not-So-Great Value

Fair Value:US$242.5% overvalued
2 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

YE
38
Yellow_fever on China Starch Holdings ·

China Starch Holdings eyes a revenue growth of 4.66% with a 5-year strategic plan

Fair Value:HK$0.562.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
PSIX logo
composite32 on Power Solutions International ·

PSIX The timing of insider sales is a serious question mark

Fair Value:US$37.3845.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TA
Talos
MRVL logo
Talos on Marvell Technology ·

The Great Strategy Swap – Selling "Old Auto" to Buy "Future Light"

Fair Value:US$155.3740.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.6% undervalued
112 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.6% undervalued
947 users have followed this narrative
6 users have commented on this narrative
24 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3407.2% undervalued
148 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative